lomerizine has been researched along with flunarizine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 10 (55.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T; Madge, DJ; Mulla, M; Riddall, D | 1 |
| Birch, PJ; Earnshaw, CG; Fiumana, A; Gilbert, J; Hobbs, CJ; James, IF; Knutsen, LJ; Mellor, SL; Radford, F; Russell Burley, J; Smith, NJ; Ward, SD | 1 |
| Belardetti, F; Ding, Y; Dolphin, D; Feng, ZP; Mitscher, LA; Pajouhesh, H; Snutch, TP; Zamponi, GW; Zhang, L | 1 |
| Hara, H; Ikegami, A; Ito, K; Ozaki, A; Sukamoto, T; Yamashita, A | 1 |
| Ikegami, A; Ito, K; Yamamoto, N; Yamashita, A; Yokota, K | 1 |
| Iwamoto, T; Morita, T; Sukamoto, T | 1 |
| Handa, J; Kidooka, M; Shiino, A | 1 |
| Ando, S; Kon, K; Tanaka, Y; Waki, H | 1 |
| Ando, S; Waki, H | 1 |
| Ito, K; Iwamoto, T; Kanazawa, T; Morita, T; Ohtaka, H | 1 |
| Akaike, N; Hara, H; Ishibashi, H; Oyama, Y; Ueha, T | 1 |
| Hara, H; Shimazawa, M; Sukamoto, T; Watano, T | 1 |
| Liou, SY; Takagi, H; Takashima, M | 1 |
| Hara, H; Hashimoto, M; Shimazawa, M; Sukamoto, T | 1 |
| Hara, H; Hashimoto, M; Iwakura, Y; Maeda, Y; Sakai, T; Sasaoka, M; Shimazawa, M; Sukamoto, T; Yamada, C; Yamaguchi, T | 1 |
| Akaike, A; Hara, H; Honda, Y; Kashii, S; Shimazawa, M; Toriu, N; Yasuyoshi, H; Zhang, S | 1 |
| Negoro, K | 1 |
| Chu, MK; Wang, SJ | 1 |
3 review(s) available for lomerizine and flunarizine
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Models, Molecular; Mutation; Nerve Tissue Proteins; Neuroprotective Agents; Protein Binding; Sodium Channel Blockers; Sodium Channels; Stroke | 2001 |
[Ca antagonists in neurosurgical practice].
Topics: Animals; Anticonvulsants; Brain; Calcium Channel Blockers; Cerebral Infarction; Disease Models, Animal; Fatty Acids, Nonesterified; Flunarizine; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Nimodipine; Piperazines; Verapamil | 1990 |
[Calcium antagonists in the prophylactic treatment of migraine].
Topics: Calcium Channel Blockers; Calcium Channels; Drug Administration Schedule; Flunarizine; Humans; Hypoxia, Brain; Migraine Disorders; Neurotransmitter Agents; Piperazines; Premedication; Vasodilation | 2009 |
15 other study(ies) available for lomerizine and flunarizine
| Article | Year |
|---|---|
Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers.
Topics: Analgesics; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Humans; Indicators and Reagents; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Thiazolidinediones | 2007 |
Scaffold-based design and synthesis of potent N-type calcium channel blockers.
Topics: Analgesics; Animals; Binding Sites; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Disease Models, Animal; Drug Design; Pain; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2009 |
Neurochemical investigation on the effects of a new diphenylpiperazine calcium antagonist, KB-2796, on the central dopaminergic system of rats.
Topics: Animals; Calcium Channel Blockers; Chlorpromazine; Corpus Striatum; Dopamine; Flunarizine; In Vitro Techniques; Male; Piperazines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Tritium | 1992 |
[Hemorheological effect of KB-2796, a new Ca2+ antagonist].
Topics: Animals; Blood Viscosity; Calcium Channel Blockers; Cerebrovascular Disorders; Erythrocyte Deformability; Flunarizine; Guinea Pigs; In Vitro Techniques; Male; Micropore Filters; Pentoxifylline; Piperazines; Rabbits | 1992 |
Calcium antagonism by KB-2796, a new diphenylpiperazine analogue, in dog vascular smooth muscle.
Topics: Animals; Binding Sites; Calcium; Calcium Channel Blockers; Cinnarizine; Dogs; Drug Interactions; Female; Flunarizine; Male; Muscle, Smooth, Vascular; Nitrendipine; Piperazines | 1991 |
Age-related changes in the uptake of calcium channel blockers by brain capillary endothelial cells and synaptosomal fractions.
Topics: Aging; Animals; Brain; Calcium Channel Blockers; Capillaries; Cerebrovascular Circulation; Endothelium, Vascular; Female; Flunarizine; Male; Osmolar Concentration; Piperazines; Rats; Rats, Inbred F344; Synaptosomes | 1990 |
Column liquid chromatography of calcium channel blockers.
Topics: Animals; Blood-Brain Barrier; Brain Chemistry; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cinnarizine; Female; Flunarizine; Piperazines; Rats; Rats, Inbred F344; Subcellular Fractions | 1989 |
Effects of KB-2796, a new calcium antagonist, and other diphenylpiperazines on [3H]nitrendipine binding.
Topics: Animals; Binding Sites; Calcium Channel Blockers; Calcium Channels; Cerebral Cortex; Flunarizine; Guinea Pigs; In Vitro Techniques; Kinetics; Male; Nitrendipine; Piperazines; Synaptosomes; Vasodilation | 1988 |
Effect of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on voltage-dependent Ca2+ currents and oxidative metabolism in dissociated mammalian CNS neurons.
Topics: Animals; Brain; Calcium Channel Blockers; Calcium Channels; Cerebellum; Dose-Response Relationship, Drug; Electric Stimulation; Evoked Potentials; Flow Cytometry; Flunarizine; Fluoresceins; Fluorescent Dyes; Hippocampus; In Vitro Techniques; Membrane Potentials; Neurons; Nystatin; Oxidation-Reduction; Piperazines; Pyramidal Tracts; Rats; Rats, Wistar | 1993 |
Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Cortical Spreading Depression; Flunarizine; Heart Rate; Histamine H1 Antagonists; Laser-Doppler Flowmetry; Male; Oncogene Proteins v-fos; Phenothiazines; Piperazines; Potassium Chloride; Rats; Rats, Wistar | 1995 |
[Effect of KB-2796, a novel calcium channel blocker, on spreading depression in rat hippocampal slices].
Topics: Animals; Calcium Channel Blockers; Cortical Spreading Depression; Flunarizine; Hippocampus; Histamine H1 Antagonists; Humans; In Vitro Techniques; Infant, Newborn; Male; Migraine Disorders; Phenothiazines; Piperazines; Rats; Rats, Sprague-Dawley; Sumatriptan | 1998 |
[Anti-migraine effects of lomerizine].
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Circulation; Cortical Spreading Depression; Flunarizine; Hippocampus; In Vitro Techniques; Migraine Disorders; Piperazines; Proto-Oncogene Proteins c-fos; Rats | 1998 |
Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cerebral Cortex; Cerebrovascular Circulation; Dogs; Dose-Response Relationship, Drug; Flunarizine; Heart Rate; Laser-Doppler Flowmetry; Male; Piperazines; Rats; Rats, Wistar; Spine | 1999 |
Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina.
Topics: Animals; Calcium Channel Blockers; Cells, Cultured; Dizocilpine Maleate; Dose-Response Relationship, Drug; Flunarizine; Glutamic Acid; Male; Neuroprotective Agents; Neurotoxicity Syndromes; Piperazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2000 |
Nomenclature for flunarizine, cinnarizine, and lomerizine.
Topics: Calcium Channel Blockers; Cinnarizine; Flunarizine; Humans; Migraine Disorders; Piperazines; Terminology as Topic | 2020 |